SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sorrento Therapeutics Inc
An SI Board Since January 2010
Posts SubjectMarks Bans Symbol
108 7 0 SRNE
Emcee:  alenor Type:  Unmoderated
Remember QBSW? Quikbyte did a reverse merger and is now:
"Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease."
Recent news starts like this:
"SAN DIEGO, Jan 11, 2010 /PRNewswire via COMTEX News Network/ --
Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA). ..."
***** MOST RECENT *****
SAN DIEGO, Aug. 1, 2013 /PRNewswire via COMTEX/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that it has filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split of its common stock, effective on July 30, 2013. The proposal to effect a reverse stock split was approved by the Company`s stockholders at its Special Meeting of Stockholders held on April 26, 2013, and the specific 1-for-25 ratio was subsequently approved by the Company`s Board of Directors. At the effective time of the reverse stock split, every twenty five shares of the Company`s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split will affect all shares of the Company`s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company`s equity incentive plans. In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split. The Company`s common stock will begin trading on the OTC QB on a split-adjusted basis when the market opens on Thursday, August 1, 2013. The new CUSIP number for the Company`s common stock following the reverse stock split is 83587F 202.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
108SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAJulius Wong-April 2
107SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREJulius Wong-March 20
106Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says Analyst finance.yahJulius Wong-11/25/2019
105Only 7 following this board? Looks like many missed out on this rocket: [tweetSI Ron (Soup Nazi)-11/25/2019
104Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash AcquisitiJulius Wong-11/25/2019
103Sorrento Jun 2019 investors.sorrentotherapeutics.comJulius Wong-6/28/2019
102Stacking The Deck: Henry Ji Is Setting The Stage For A Sorrento Therapeutics BreJulius Wong-6/27/2019
101Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic ApproaJulius Wong-4/10/2019
100Sorrento Therapeutics April 2019 Presentation investors.sorrentotherapeutics.coJulius Wong-4/7/2019
99FORM 8-K sec.govJulius Wong-4/3/2019
98Sorrento Therapeutics Sues Billionaire Soon-Shiong Over Development of Cancer DrJulius Wong-4/3/2019
97Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a GlobJulius Wong-3/22/2019
96SRNE March presentation investors.sorrentotherapeutics.comJulius Wong-3/20/2019
95Sorrento Therapeutics, Inc. [graphic]Julius Wong-3/18/2019
94Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer Sponsor: Julius Wong-2/6/2019
93Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(Julius Wong-1/14/2019
92Sorrento Therapeutics, Inc. [graphic]Julius Wong-9/10/2018
91Looking Ahead At Catalysts – Sorrento Therapeutics (SRNE) seekingalpha.comJulius Wong-8/5/2018
90Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders finaJulius Wong-6/15/2018
89Hong Kong market could open cash flood gates for U.S. biotechs finance.yahoo.coJulius Wong-6/14/2018
88Sorrento Therapeutics, Inc. [graphic]Julius Wong-5/24/2018
87Sorrento Therapeutics Receives a Buy from Oppenheimer analystratings.comJulius Wong-3/20/2018
86FDA approves Sorrento's non-opioid painkiller patch, shares jump finance.yaJulius Wong-3/1/2018
85celgene-spinout-celularity-raises-250-million-to-develop-placental-cells-to-attaJulius Wong-2/20/2018
84Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholders finance.yahoo.cJulius Wong-2/5/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):